(Q44369766)

2 December 2017

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study (English)

1 reference

2 December 2017

1 reference

endometrial carcinoma

1 reference

1 reference

1 reference

Sarah Lincoln

1

1 reference

2 December 2017

John A Blessing

series ordinal

2

1 reference

2 December 2017

Roger B Lee

series ordinal

3

1 reference

2 December 2017

Thomas F Rocereto

series ordinal

4

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

2 December 2017

5

1 reference

inferred from page(s)

published in

Gynecologic Oncology

1 reference

2 December 2017

88

1 reference

2 December 2017

3

1 reference

2 December 2017

277-281

1 reference

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Taxol is active in platinum-resistant endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Teniposide (VM-26) in patients with advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

A phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900068-9

7 January 2021

10.1016/S0090-8258(02)00068-9

Identifiers

DOI

1 reference

release_abrrlunolfgxzflgs7b3fxoy3e

2 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/abrrlunolfgxzflgs7b3fxoy3e

24 November 2022

mapped directly with Wikidata item

1 reference